Guidant takes smaller heart failure device to US:
This article was originally published in Clinica
The US FDA has approved Guidant's next-generation implantable device for treating heart failure - the CONTAK CD 2 cardiac resynchronisation therapy defibrillator (CRT-D). Measuring just 41cc, the physiologically shaped product is around 38% smaller than any competing CRT-D system in the US, claims the company. The device combines cardiac resynchronisation therapy with an implantable defibrillator to improve the quality of life for heart failure patients and protect them from sudden cardiac death.